Table 5.
Demographic comparison of “unstable” ITP drawn from historical cohort vs relapsed ITP after COVID-19 vaccination.
| “Unstable” historical cohort (n = 6) | Relapsed ITP after COVID-19 vaccination (n = 13) | P | |
|---|---|---|---|
| Sex (female, %) | 3 (50) | 9 (69) | |
| Age (median, y) | 71 | 64 | |
| Splenectomy (%) | 2 (33) | 1 (8) | |
| Stable off treatment (%) | – | 11 (85) | .001 |
| TPO-RA (%) | 5 (83) | 2 (15) | .01 |
| Baseline platelets (median, ×109/L) | 122 [IQR 38-203] | 132 [IQR 46-202] | |
| Nadir platelets (median, ×109/L) | 27 [IQR 13-37] | 6 [IQR 4.5-12] | .005 |
| Postnadir platelets (median, ×109/L) | 77 [IQR 45-225] | 89 [IQR 31-156] |
ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.